China Biopharmaceutical (01177) will pay a final dividend of HK$0.03 per share on July 5
China Biopharmaceutical (01177) announced that the company will pay a final dividend of 0 per share on July 5, 2024...
China Biopharmaceutical (01177) announced annual results. Profit attributable to shareholders of 2,332 billion yuan decreased by 8.32% year-on-year to increase investment in R&D
According to the Zhitong Finance App, China Biopharmaceutical (01177) announced results for the year ended December 31, 2023. The group achieved continuous operating revenue of 26.199 billion yuan (RMB, same below) during the period, an increase of 0.67%; profit attributable to shareholders of 2,332 billion yuan, a year-on-year decrease of 8.32%; basic profit per share of 12.59 points; and plans to distribute a final dividend of HK3 cents per share. The announcement stated that the Group has always attached great importance to R&D, combining R&D concepts of independent innovation, joint development and imitation development, continuously improving the level and speed of R&D, and regards it as the foundation for sustainable development
SINO BIOPHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China
Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration gave the marketing approval to its Iopromide Injection, according to a Hong Kong bourse filing on Monday. The in
China Biopharmaceutical (01177.HK): Medical imaging product “iopromide injection” approved for listing
On March 25, Ge Longhui | China Biopharmaceutical (01177.HK) announced that the medical imaging product iopromide injection (trade name: polyiodine) developed by the Group has obtained marketing approval from China's State Drug Administration. For diagnostic use, it can be used for intravascular and intra-body imaging. According to the disclosure, iopromide is a triiodized non-ionic water-soluble X-ray contrast agent with high iodine content and good contrast effect. It is mostly used for computer X-ray tomography (CT) enhancement, arteriography and venography, endoscopic retrograde cholangiopancreatography (ERCP), joint cavity imaging, and other body cavity tests
Sino Biopharmaceutical's Developing Two Drugs for MASH
Sino Biopharmaceutical (HKG:1177) said two drugs, lanifibranor (pan-PPAR agonist) and TQA2225, jointly developed by the group, are undergoing Phase III and Phase II clinical trials, respectively in Ch
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy
06:23 AM EDT, 03/15/2024 (MT Newswires) -- Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy Price (HKD): $3.26, Change: $-0.04, Percent Change: -1.21%
China Biopharmaceutical (01177.HK): “ranilano” (pan-PPAR agonist) and “TQA2225" (recombinant human FGF21-FC fusion protein) are currently undergoing phase III and phase II clinical trials in China, respectively
Gelonghui, March 15 | China Biopharmaceutical (01177.HK) announced that “ranilano” (pan-PPAR agonist) and “TQA2225" (recombinant human FGF21-FC fusion protein) jointly developed by the group are currently undergoing phase III and phase II clinical trials in China, respectively, for the treatment of fatty hepatitis associated with metabolic dysfunction. Lanilano is an oral small molecule drug that regulates anti-fibrosis and anti-inflammatory pathways in the body by activating three peroxisomal proliferator-activated receptor (“PPAR”) subtypes. In the NativeIB Phase IB study, Rani Lannoch
Nomura: Reiterates China Biopharmaceutical's “Buy” Rating Target Price Reduced to HK$6.16
According to a research report released by Nomura, the profit of China Biopharmaceuticals (01177) in the second half of last year is expected to achieve high growth on a low year-on-year basis, and the Group also expects more business development transactions, sale of non-core subsidiaries and new drug listings in the 2024 fiscal year. In addition, Zhongsheng Pharmaceutical's sales forecasts for the 2023 and 2024 fiscal years were lowered by 5.6% and 7.3%, respectively, while profit estimates were lowered by 12.2%, respectively. However, the bank reiterated its “buy” rating and the target price was reduced from HK$6.63 to HK$6.16.
Nomura: Reiterates China Biopharmaceutical's (01177) “Buy” Rating Target Price Reduction to HK$6.16
Nomura lowered Chusei Pharmaceutical's sales forecast for fiscal year 2023 and 2024 by 5.6% and 7.3%, respectively.
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR
Sino Biopharmaceutical (HKG:1177) said it will present the findings of the phase II clinical study of KRAS G12C Inhibitor Garsorasib Tablet at the Annual Meeting 2024 of the American Association for C
Changes in Hong Kong stocks | China Biopharmaceuticals (01177) rose more than 4%, two innovative drugs will announce a total of 5 research results at AACR
China Biopharmaceuticals (01177) rose more than 4%. As of press release, it rose 4.06% to HK$3.33, with a turnover of HK$281 million.
Glonghui Announcements Selected (Hong Kong Stocks) | Samsonite (01910.HK)'s annual profit attributable to shareholders of US$417 million increased 33.3% year-on-year
[Today's Focus] Samsonite (01910.HK)'s annual profit attributable to shareholders of $417 million increased 33.3% year on year. Samsonite (01910.HK) announced that for the year ended December 31, 2023, the company's net sales were 3,682.4 million US dollars, up 27.9% year over year (30.0% increase on a constant exchange rate basis). Excluding Russia's net sales, the consolidated net sales for the year ended 31 December 2023 increased by $812.5 million, or 28.3%, compared to the year ended 31 December 2022 (
China Biopharmaceutical (01177): Phase II clinical study data for the KRAS G12C inhibitor “GARSORASIB (D-1553 tablets)” will be announced at 2024 AACR
Zhitong Finance App News, China Biopharmaceutical (01177) announced that the KRAS G12C inhibitor “Garsorasib (D-1553 tablets)” jointly developed by the group will announce the latest results of the Phase II clinical study (NCT05383898) at the 2024 American Cancer Association Annual Meeting (AACR) to treat patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutations.
Changes in Hong Kong stocks | Zhongsheng Pharmaceutical (01177) rose more than 5%, two innovative drugs, a total of 5 research data will be released in 2024 AACR
China Biopharmaceutical (01177) is now up more than 5%. As of press release, it has risen 5.37% to HK$3.14, with a turnover of HK$39.03 million.
China Biopharmaceutical (01177.HK) “anlotinib hydrochloride capsules” and “TQB2916 (CD40 agonist)” will be published in 2024AACR
Gelonghui, March 11 | China Biopharmaceutical (01177.HK) announced that the two innovative drugs “anlotinib hydrochloride capsules” and “TQB2916 (CD40 agonist)” developed by the group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Zhengda Tianqing”), will present 5 research results at the 2024 American Cancer Association Annual Meeting (“AACR”). Anlotinib is a novel oral small-molecule multi-target receptor tyrosine kinase inhibitor (TKI) independently developed by Zhengda Tianqing. It can effectively inhibit VEGFR1-3, PDGFRα/beta, FGFR1-4, c-
Changes in Hong Kong stocks | Zhongsheng Pharmaceutical (01177) is now down more than 5%, Citi says minority shareholders' equity percentage has been offset to lower earnings per share
Zhongsheng Pharmaceutical (01177) is now down more than 5%. As of press release, it is down 5.4% to HK$2.98, with a turnover of HK$87.326 million.
China Biopharmaceutical (01177.HK) plans to hold a board meeting on March 28 to approve annual results
Gelonghui, March 1, 丨 China Biopharmaceutical (01177.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to approve (among other things) the publication of the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider the proposed payment of a final dividend (if any).
SINO BIOPHARM: NOTIFICATION OF BOARD MEETING
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
No Data